Relative Bioavailability Study of a New Medium/Long-chain Triglyceride Emulsion of Propofol in Beagle Dogs

W. Chen; Y.-Q. Cai

doi:10.1055/s-0033-1349125

Drug Research, Inhaltsverzeichnis

Drug Res (Stuttg) 2013; 63(11): 568-571
DOI: 10.1055/s-0033-1349125

Original Article

Relative Bioavailability Study of a New Medium/Long-chain Triglyceride Emulsion of Propofol in Beagle Dogs

W. Chen

¹Department of Anesthesiology, Zhongshan Hospital, Fudan University, Shanghai, China

,

Y.-Q. Cai

²Department of Clinical Pharmacology, Shanghai New Drugs Research and Development Center, Shanghai, China

› Institutsangaben

Abstract

The aim of this study was to evaluate the bioequivalence of a new generic formulation of propofol medium/long-chain triglyceride emulsion (test) and the available branded formulation (reference) to comply with regulatory criteria for marketing of the test product in China. This single-dose, randomized-sequence, open-label, 2-period crossover study was conducted in 6 beagle dogs. Blood samples were collected before dosing and at different time after dosing. Plasma samples were separated and assayed for propofol using a selective and sensitive HPLC method with fluorescence detection. The pharmacokinetic parameters AUC_0-T, AUC_0-∞, MRT, t_1/2 and CL were determined from plasma concentration-time profile of both formulations. The formulations were considered bioequivalent when the 90% CIs of the geometric mean ratios (test:reference) for AUC_0-T and AUC_0-∞ were within the regulatory range of 80% to 125%.

Key words

propofol - HPLC - fluorescence detection - pharmacokinetic parameters

Volltext

Referenzen

References
1 Christensen BV, Thunedborg LB. Use of sedatives, analgesics and neuromuscular blocking agents in Danish ICUs 1996/97: a national survey. Intensive Care Med 1999; 25: 186-191
2 Murdoch S, Cohen A. Intensive care sedation: a review of current British practice. Intensive Care Med 2000; 26: 922-928
3 McCollam JS, O’Neil MG, Norcross D et al. Continuous infusions of lorazepam, midazolam, and propofol for sedation of critically ill surgery trauma patient: a prospective, randomized comparison. Crit Care Med 1999; 27: 2454-2458
4 Ronan KP, Gallagher TJ, George B et al. Comparison of propofol and midazolam for sedation in intensive care unit patients. Crit Care Med 1995; 23: 286-293
5 Carrasco G, Molina R, Costa J et al. Propofol vs midazolam in short-, medium-, and longterm sedation of critically ill patients: a cost-benefit-analysis. Chest 1993; 103: 557-564
6 Barrientos-Vega R, Sanchez-Soria MM, Morales-Garcia C et al. Prolonged sedation of critically ill patients with midazolam or propofol: impact on weaning and costs. Crit Care Med 1997; 25: 33-40
7 Gouldson R, Nathanson M, White PF et al. Propofol: An update on its clinical use. ANESTHESIOLOGY 1994; 81: 1005-1043
8 Crowther J, Hrazdil J, Jolly DT et al. Growth of microorganisms in propofol, thiopental, and a 1:1 mixture of propofol and thiopental. Anesth Analg 1996; 82: 475-478
9 Fulton B, Sorkin EM. Propofol: an overview of its pharmacology and a review of its clinical efficacy in intensive care sedation. Drugs 1995; 50: 636-657
10 Wicklmayr M, Rett K, Dietze G et al. Comparison of metabolic clearance rates of MCT/LCT and LCT emulsions in diabetics. J Parenter Enteral Nutr 1988; 12: 68-71
11 Jeevanandam M, Holaday NJ, Voss T et al. Efficacy of a mixture of medium-chain triglyceride (75%) and long-chain triglyceride (25%) fat emulsions in the nutritional management of multipletrauma patients. Nutrition 1995; 11: 309-310
12 US FDA. Guidance for Industry-Bioanalytical Method Validation. US Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research, Center for Veterinary Medicine; May 2001. Available from: http://www/fda.gov/cder/guidance/index.htm